読み込み中
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
前日終値
$4.36
+$0.41 · +10.38%
日中の時刻はETです。市場データは遅延する場合があります。
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
日中レンジ
現在 $4.36
52週レンジ
現在 $4.36
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
50
適正価値
センチメント
62
強気
リスク
63
高リスク
モメンタム
44
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
日中レンジ
現在 $4.36
52週レンジ
現在 $4.36
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 7468.1万 USD | 5883.9万 USD | 4387.6万 USD | 3968.1万 USD | 1000万 USD |
| 売上原価 | 1.21億 USD | 4523.8万 USD | 4258.7万 USD | 4827.5万 USD | — |
| 粗利益 | −4627.3万 USD | 1360.1万 USD | 128.9万 USD | −859.4万 USD | 1000万 USD |
| 研究開発 | 4.25億 USD | 3.14億 USD | 2.41億 USD | 1.56億 USD | 1.35億 USD |
| 販売・一般管理 | 1.77億 USD | 1.78億 USD | 1.11億 USD | 8159.9万 USD | 5768.2万 USD |
| 営業費用 | 6.02億 USD | 4.93億 USD | 3.51億 USD | 2.37億 USD | 1.93億 USD |
| 受取利息 | 2278.8万 USD | 1575.8万 USD | 1911.6万 USD | 625.4万 USD | 7.3万 USD |
| 支払利息 | 181万 USD | 157.2万 USD | 9.7万 USD | 5.5万 USD | 295.2万 USD |
| 減価償却費と償却費 | 8370.1万 USD | 3649.4万 USD | 2440.2万 USD | 1175.6万 USD | 840.5万 USD |
| 営業利益 | −6.48億 USD | −4.79億 USD | −3.5億 USD | −2.46億 USD | −1.83億 USD |
| 純利益 | −6.45億 USD | −4.64億 USD | −3.28億 USD | −2.39億 USD | −1.86億 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
ARK Innovation ETFARKK8722.7万1.27%55.62億 USD0.75%$89.62+2.31%
State Street SPDR S&P Biotech ETFXBI6649.93万0.67%98.74億 USD0.35%$153.77+3.00%
ARK Genomic Revolution ETFARKG5817.27万2.84%15.57億 USD0.75%$51.30+4.08%
Vanguard Morningstar Total Stock Market ETFVTI5404.89万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM5349.14万0.07%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB3897.36万0.02%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK2232.72万0.05%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF2071.17万0.02%954億 USD0.05%$235+0.80%ARK Innovation ETFARKKState Street SPDR S&P Biotech ETFXBIARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
